[ad_1]
This Monday the American multinational Johnson & Johnson reported that due to an unexplained illness in a study participant, clinical trials of the vaccine have been paused.
(Can read: 5 things everyone should know to avoid new waves of the pandemic)
“We have temporarily stopped additional dosing in all of our covid-19 vaccine candidate clinical trials, including the ENSEMBLE phase 3 trial, due to unexplained illness in a study participant. Following our guidelines, the participant’s illness is being reviewed and evaluated by the Data Security Monitoring Board “, they assured.
They also said that “adverse events (illnesses, accidents, etc.), even those that are serious, are an expected part of any clinical trial, especially large studies.”
In the statement they issued they explained that out of respect for the privacy of the participant who presented the disease they will not issue more information about it while they study in depth what happened to him during the trials.
(We recommend: The first Colombian to receive the covid-19 vaccine spoke)
How is this vaccine?
The Johnson & Johnson vaccine against the new coronavirus is of the vector type, which uses adenovirus serotype 26 (Ad26) which, according to an article published in the journal Nature on July 30, produced a robust immune response with neutralizing antibodies.
These antibodies came, according to the researchers, from a specific infection that projects complete or almost complete protection against Sars-CoV-2 of the lungs in non-human primates.
A decade ago, researchers at the Beth Israel Deaconess Medical Center in Boston developed a method for making vaccines from adenovirus 26 (Ad26). Johnson & Johnson, based on this technology, developed vaccines for Ebola and other diseases, which has allowed it to advance in the manufacture of one for covid-19.
According to information from The New York Times in March, the United States Government contributed 456 million dollars to this project, which in phases I and II demonstrated protection in non-human primates.
(We suggest you read: This is how Colombia stopped producing vaccines)
Since then, J&J announced phase III trials that would cover 60,000 people by the end of September. In this sense, it is known that it will also be tested in 180 places in the United States as well as in countries such as Mexico and Brazil.
The federal government of the United States has agreed to pay $ 1 billion for 100 million doses if the vaccine is approved. The company’s claims aim to produce at least 1 billion doses by 2021.
With the announcement on Monday, for now, plans to continue testing the vaccine are on hold.
More Health news:
– Coronavirus can survive up to 28 days on cell phones, according to study
– Ghosts of new pandemic peaks are already looming in various regions
– Cabin syndrome, fear of leaving after quarantine
ELTIEMPO.COM
